Accuray Incorporated
| NASDAQ: ARAY | Healthcare / Medical Devices & Instruments / USA |
| 5.16 | -0.0500 | -0.96% | Vol 486.57K | 1Y Perf 190.96% |
| Apr 19th, 2021 16:00 DELAYED |
| BID | 4.85 | ASK | 5.30 | ||
| Open | 5.15 | Previous Close | 5.21 | ||
| Pre-Market | - | After-Market | 5.16 | ||
| - - | - -% |
| Target Price | 7.33 | Analyst Rating | Moderate Buy 2.00 | |
| Potential % | 42.05 | Finscreener Ranking | ★★+ 48.17 | |
| Insiders Trans % 3/6/12 mo. | -100/-75/-80 | Value Ranking | ★+ 43.30 | |
| Insiders Value % 3/6/12 mo. | -100/-23/-32 | Growth Ranking | ★★+ 48.72 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-21/-34 | Income Ranking | — - | |
| Market Cap | 479.35M | Earnings Rating | Neutral | |
| Price Range Ratio 52W % | 80.37 | Earnings Date | 27th Apr 2021 |
Today's Price Range 5.065.21 | 52W Range 1.686.01 | 5 Year PE Ratio Range -12.00-14.50 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -1.15% | ||
| 1 Month | -0.58% | ||
| 3 Months | -4.09% | ||
| 6 Months | 63.03% | ||
| 1 Year | 190.96% | ||
| 3 Years | 2.18% | ||
| 5 Years | -15.41% | ||
| 10 Years | -43.67% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -33.16 | |||
ROE last 12 Months | 11.02 | |||
ROA (5Y Avg) | -3.92 | |||
ROA last 12 Months | 1.53 | |||
ROC (5Y Avg) | -5.10 | |||
ROC last 12 Months | 2.72 | |||
Return on invested Capital Q | 1.69 | |||
Return on invested Capital Y | -0.29 | |||
Assets Turnover | 0.60 | |||
Receivables Turnover | 3.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 61.70 | ||||
| 6.22 | ||||
| 1.73 | ||||
| 20.70 | ||||
| 14.60 | ||||
| 0.25 | ||||
| 25.12 | ||||
| 0.84 | ||||
| 586.84M | ||||
| Forward PE | 57.88 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.00 | ||||
| 1.90 | ||||
| 0.71 | ||||
| 2.70 | ||||
| 1.40 | ||||
| Leverage Ratio | 6.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 41.10 | ||||
| 10.10 | ||||
| 12.00 | ||||
| -4.20 | ||||
| 1.76 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 277.77M | ||||
| 2.99 | ||||
| -6.89 | ||||
| -2.91 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2021 | -0.01 | 0.05 | 600.00 |
| Q01 2021 | -0.09 | 0.00 | 100.00 |
| Q04 2020 | 0.02 | -0.01 | -150.00 |
| Q03 2020 | -0.03 | 0.03 | 200.00 |
| Q02 2020 | -0.07 | 0.01 | 114.29 |
| Q01 2020 | -0.10 | -0.11 | -10.00 |
| Q04 2019 | 0.03 | -0.02 | -166.67 |
| Q03 2019 | -0.04 | -0.01 | 75.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | 0.01 | -66.67 | Negative |
| 6/2021 QR | 0.00 | -100.00 | Negative |
| 6/2021 FY | 0.05 | 150.00 | Positive |
| 6/2022 FY | 0.09 | 0.00 | - |
| Next Report Date | 27th Apr 2021 |
| Estimated EPS Next Report | 0.01 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 486.57K |
| Shares Outstanding | 92.90M |
| Trades Count | 3.97K |
| Dollar Volume | 5.07M |
| Avg. Volume | 864.59K |
| Avg. Weekly Volume | 404.32K |
| Avg. Monthly Volume | 597.42K |
| Avg. Quarterly Volume | 868.61K |
Accuray Incorporated (NASDAQ: ARAY) stock closed at 5.16 per share at the end of the most recent trading day (a -0.96% change compared to the prior day closing price) with a volume of 486.58K shares and market capitalization of 479.35M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 932 people. Accuray Incorporated CEO is Joshua H. Levine.
The one-year performance of Accuray Incorporated stock is 190.96%, while year-to-date (YTD) performance is 23.74%. ARAY stock has a five-year performance of -15.41%. Its 52-week range is between 1.68 and 6.01, which gives ARAY stock a 52-week price range ratio of 80.37%
Accuray Incorporated currently has a PE ratio of 61.70, a price-to-book (PB) ratio of 6.22, a price-to-sale (PS) ratio of 1.73, a price to cashflow ratio of 20.70, a PEG ratio of 2.32, a ROA of 1.53%, a ROC of 2.72% and a ROE of 11.02%. The company’s profit margin is 1.76%, its EBITDA margin is 12.00%, and its revenue ttm is $277.77 Million , which makes it $2.99 revenue per share.
Of the last four earnings reports from Accuray Incorporated, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.01 for the next earnings report. Accuray Incorporated’s next earnings report date is 27th Apr 2021.
The consensus rating of Wall Street analysts for Accuray Incorporated is Moderate Buy (2), with a target price of $7.33, which is +42.05% compared to the current price. The earnings rating for Accuray Incorporated stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Accuray Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Accuray Incorporated has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.76, ATR14 : 0.27, CCI20 : 46.61, Chaikin Money Flow : -0.08, MACD : -0.01, Money Flow Index : 74.13, ROC : 4.24, RSI : 46.97, STOCH (14,3) : 73.49, STOCH RSI : 0.00, UO : 52.23, Williams %R : -26.51), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Accuray Incorporated in the last 12-months were: Jesse Chew (Sold 9 009 shares of value $28 020 ), Joseph E. Whitters (Buy at a value of $173 135), Joshua H. Levine (Sold 31 044 shares of value $101 170 ), Michael Hoge (Sold 11 268 shares of value $62 199 ), Patrick Spine (Sold 6 425 shares of value $19 407 ), Shigeyuki Hamamatsu (Sold 19 294 shares of value $53 187 ), Suzanne Winter (Sold 23 740 shares of value $71 714 )
Accuray Incorporated
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. CyberKnife Systems requires no anesthesia, and treatment sessions are done on an outpatient basis.
CEO: Joshua H. Levine
Telephone: +1 408 716-4600
Address: 1310 Chesapeake Terrace, Sunnyvale 94089, CA, US
Number of employees: 932
